All In Biotech

Drug Trial Radar · NCT06020560

Study of Low Molecular Weight Heparins

Cluster-randomized Trial of Low Molecular Weight Heparins - Directly Through EPIC

Last checked: Nov 19, 2026Latest source record: Aug 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 65,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

65,000

Planned (sponsor's estimate)

Start

Mar 23, 2023

Primary completion

Mar 23, 2025

Study completion Mar 23, 2025

Sponsor

Lead sponsor
Herlev HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 31, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

DANHEP is a cluster randomized study of two different low molecular weight heparins. Parenteral anticoagulants are used in a variety of settings, including treatment and prevention of venous thromboembolism in cancer patients, medical patients, and surgical patients, along with the use as adjuvant therapy for coronary syndromes. The most frequently used parenteral anticoagulants in Denmark, include the two different low molecular weight heparins; dalteparin and tinzaparin. The two drugs are considered equally efficient and safe regarding treatment and prevention of thrombosis and risk of bleeding. Importantly, there is a lack of evidence regarding whether these drugs are in fact comparable. The aim of this study is therefore to investigate the comparative safety and efficacy of the two different low molecular weight heparins (dalteparin and tinzaparin using cluster randomization in patients with an indication for low molecular weight heparins.

Conditions

  • Anticoagulant
  • Venous Thromboembolism
  • Prophylaxis
  • Treatment

Interventions

  • Dalteparin Prefilled SyringeDrug

    Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour.

  • Tinzaparin profiled syringeDrug

    Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 30-day all-cause mortality and bleeding requiring blood transfusionTime frame: 30 days

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Amager-Hvidovre Hospital

    Copenhagen, Denmark · Recruiting

  • Frederiksberg and Bispebjerg Hospital

    Copenhagen, Denmark · Recruiting

  • Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • Herlev and Gentofte Hospital

    Herlev, Denmark · Recruiting

  • Nordsjællands Hospital

    Hillerød, Denmark · Recruiting

  • Næstved, Ringsted, Slagelse Hospital

    Næstved, Denmark · Recruiting

  • Nykøbing Falster Hospital

    Nykøbing Falster, Denmark · Recruiting

  • Bornholm Hospital

    Rønne, Denmark · Recruiting

  • Roskilde, Køge Hospital

    Roskilde, Denmark · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.